Geron announces Conference Call for Third Quarter

Geron Announces Conference Call to Discuss Third Quarter Financial Results and Highlights. November 4, 2011 at 9AM Eastern Time. Dial 1-800-706-7748 the passcode is 53572623.

More good data from GRNOPC1

Oct 25, 2011 07:31:09 (ET)

MENLO PARK, Calif., Oct 25, 2011 (BUSINESS WIRE) -- Geron Corporation (GERN, Trade)
today announced data on the use of GRNOPC1, oligodendrocyte progenitors derived from
 human embryonic stem cells, for myelin repair in a non-human primate model. The data supports
 further investigation of the potential therapeutic use of GRNOPC1 in central nervous system
(CNS) disorders where the central or contributing pathology is destructive removal of myelin
 from nerve axons, such as observed in multiple sclerosis (MS), myelitis and spinal cord injury.
 GRNOPC1 is currently in a Phase 1 clinical trial in patients with spinal cord injury.The new
data were presented at the 5th Joint Triennial Congress of the European and Americas Committees
 for Treatment and Research in Multiple Sclerosis, in Amsterdam, by Prof. Jeffery D. Kocsis,
 Ph.D., from Yale University School of Medicine. The work was performed in collaboration
with scientists at Geron.
The studies utilized a non-human primate model where demyelinated lesions, such as seen
in multiple sclerosis, were induced chemically in the spinal cord. GRNOPC1 was injected
 into the demyelinated spinal cord lesions one week after chemical induction. The lesion sites
 from six monkeys were analyzed using light and electron microscopy at various timepoints
 up to one year after injection of GRNOPC1 to look for evidence of cell survival and
remyelination of nerve axons. In the first few weeks  after implantation, the injection sites
contained maturing transplanted cells indicative of a premyelinating phenotype with evidence
 of variable numbers and degrees of remyelinated axons. By four months post implantation,
GRNOPC1 had induced extensive and thick myelin around the formerly denuded axons.
Human cells were detected at the lesion site, providing evidence for survival of
 transplanted GRNOPC1. There was no evidence of abnormal tissue, tumor formation or
other pathologies associated with the injection of GRNOPC1. Neurological exams of the injected
 animals were normal. The data showed in the non-human primate that GRNOPC1 can survive
 at the lesion site and progressively remyelination of axons. "These new data confirm and
extend previous results showing that GRNOPC1 can promote remyelination in rodents and
 non-human primates," said Jane Lebkowski, Ph.D., Geron's Chief Scientific Officer. "These
 results provide  further support for the potential of GRNOPC1 to provide therapeutic
benefit in a number of central nervous system diseases, such as MS and myelitis."
About GRNOPC1
Oligodendrocytes produce myelin, an insulating layer made up of protein and fatty substances
 that forms around nerves in the CNS to enable them to conduct electrical signals. Without
 myelin, many of the nerves in the brain and spinal cord cannot function properly. Oligodendrocytes
 are lost in CNS disorders such as spinal cord injury and MS.
GRNOPC1 contains hESC-derived oligodendrocyte progenitor cells that have demonstrated
remyelinating, nerve growth stimulating and angiogenic properties leading to restoration
 of function in rodent models of acute spinal cord  injury. Non-clinical studies have shown that 

administration of GRNOPC1 seven days after injury significantly improved locomotor activity
and kinematic scores of rats with spinal
About Geron
Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic
degenerative diseases. The company is advancing anti-cancer therapies through multiple
Phase 2 clinical trials in different cancers by targeting the enzyme telomerase and
 with a compound designed to penetrate the blood-brain barrier. The company is developing
 cell therapies from differentiated human embryonic stem cells, with the first product in a
Phase 1 clinical trial for spinal cord injury.
 For more information, visit www.geron.com .

Safety data on GRNOPC1

Safety data to data form the trial has shown:

1.No surgical complications during or after the procedures.
2.No adverse events related to the injection procedures or to GRNOPC1.
3.A few mild adverse events related to tacrolimus.
4.No evidence of cavitation in the spinal cord at the injury sites on MRI.
5.No unexpected neurological changes.
6.No evidence of immune responses to GRNOPC1.

GRNOPC1 was delivered to four spinal cord injured patients at a dose of two million cells without complications from either the cells or the surgical procedure itself, and without any negative effects on the spinal cord or neurological function of the patients to date. The only side-effects observed were due to the immunosuppressive drug tacrolimus, which is administered for the first two months after injection of GRNOPC1. Furthermore, there is no evidence to date of immune rejection of GRNOPC1, an allogeneic cell therapy, including after withdrawal of immunosuppressive drug.
The facts all point to success. We know that these stem cells work. The big question is whether they are safe. We have shown that to date.  Geron is positioned for huge increases from this and Oncology programs. Then orchestrated takeover bid most likely scenario, as any review of the new CEO will indicate. Those are the facts.  Stock moves up. Market as well.


Good luck in this rigged casino,

No Interest

Five day avg volume only 1,084,860 shares, ten day avg. 1,281,746 and three month avg. 1,651,130 shares. Market has no real interest in Geron at this time. The high for the week was $2.38 on Monday and low was $2.11 on Wednesday. Share price has been range bound from Sept 22-Oct 21,  between $1.87 to $2.38. Only under $2, two days and closed over $2 on those days. Will be buying more on any dips close to $2.

Good luck in this rigged casino,

GERON the future in bio-tech: Manipulation

GERON the future in bio-tech: Manipulation: Yes, manipulation of share price does happen and is happening. If we get a toe wiggle or the results from the four Phase 2 cancer drug appe...

Manipulation

Yes, manipulation of share price does happen and is happening. If we get a toe wiggle or the results from the four Phase 2 cancer drug appears to be successful none of the Market Makers, hedge funds or institutions will be capable of stopping the huge run up.  The market is bigger then any Market Maker or hedge fund.  When things are in doubt, fear can be planted and exploited.  The Market Makers, hedge funds and institutions will take advantage. They cover, they switch sides but they are not stupid enough to try an stop a big move up. If you believe like I do buy a few shares on the dips. Many are shorting and or are selling, when they should be accumulating.  Always, Always remember to can lose all your money in any stock.

Good luck in this rigged casino,

Geron Q and A Dr. Gold

Dr.Gold, "So far 4 patients have been treated, It was never our intent to publicize their identities or their progress. The first patient was treated a year ago. No adverse effects whatsoever, which was the goal, because it allows us to ramp up the dose from a "safety" range to a "beneficial function" range. Going forward, there will be cervical patients, higher doses, and efforts to break up the scar tissue so that whatever works in subacutes also helps chronics."
Then Q and A
Q: Dr Gold, please tell us something about the patients you've treated at Geron.
A: No, I'm not allowed to talk about that. I do need to say that we'd be delighted, of course.
This is good news, Geron is moving forward. With some luck we might get a toe wiggle. If not now, later with the higher doses.
Good luck in this rigged casino,